Jacobs Levy Equity Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Jacobs Levy Equity Management’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-42,306	Closed	-$133K	–	1160
2019 Q4	$133K	Hold	42,306	–	–	﹤0.01%	965
2019 Q3	$190K	Sell	42,306 -1,466	-3%	-$7.33K	﹤0.01%	853
2019 Q2	$208K	Buy	43,772 +12,887	+42%	+$61.1K	﹤0.01%	875
2019 Q1	$169K	Sell	30,885 -22,758	-42%	-$105K	﹤0.01%	909
2018 Q4	$163K	Hold	53,643	–	–	﹤0.01%	907
2018 Q3	$225K	Buy	53,643 +5,593	+12%	+$23.6K	﹤0.01%	914
2018 Q2	$186K	Sell	48,050 -10,677	-18%	-$70.9K	﹤0.01%	963
2018 Q1	$372K	Buy	58,727 +32,799	+127%	+$271K	0.01%	826
2017 Q4	$209K	Buy	25,928 +8,642	+50%	+$80.6K	﹤0.01%	900
2017 Q3	$198K	Buy	+17,286	New	+$182K	﹤0.01%	866
2016 Q3	–	Sell	-5,389	Closed	-$229K	–	1220
2016 Q2	$229K	Buy	+5,389	New	+$294K	﹤0.01%	979

Other funds holding MACK

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

WSL

Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sepio Capital Salt Lake City, Utah $1.99B AUM 22.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WIM

Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return

LPIC

LeJeune Puetz Investment Counsel Traverse City, Michigan $279M AUM 4.39% 1-Year Est. Return

Jacobs Levy Equity Management's MACK Position: Q1 2020 in Review

Jacobs Levy Equity Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2020, closing a stake of 42,306 shares — an estimated $133K sold.

Jacobs Levy Equity Management first reported a position in MACK in Q2 2016 and held it in 11 quarters. The position peaked at $372K in Q1 2018. 37 funds tracked by Wall St. Rank hold MACK as of Q1 2020.

Jacobs Levy Equity Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
Jacobs Levy Equity Management sold 42,306 Merrimack Pharmaceuticals, Inc. shares in Q1 2020, an estimated $133K.
Jacobs Levy Equity Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2016 and held it in 11 quarters.
Jacobs Levy Equity Management's Merrimack Pharmaceuticals, Inc. position peaked at $372K in Q1 2018.
37 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2020.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2020, filed 15 May 2020.